Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p.

Liu Z, Zhou Y, Liang G, Ling Y, Tan W, Tan L, Andrews R, Zhong W, Zhang X, Song E, Gong C. · 2019

Read Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. by Liu Z, Zhou Y, Liang G, Ling Y, Tan W, Tan L, Andrews R, Zhong W, Zhang X, Song E, Gong C. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6343010.txt.

Introduction

Liu and co-authors identify a circular RNA that pushes breast cancer forward. Their study appeared in Cell Death and Disease. Circular RNAs often work by sponging microRNAs. The team screened breast cancer circRNAs by computer first. One, hsa_circ_001783, ranked at the top. Tests confirmed it runs high in cancer tissue and cells.

Higher levels meant heavier tumors and poorer survival. Silencing the ring slowed cell growth and invasion. It acts by soaking up the microRNA miR-200c-3p. That microRNA normally restrains cancer cell behavior. Freeing its targets lets progression resume. The authors propose the ring as a prognostic marker. They also name it a possible treatment target. The work adds breast cancer to the circRNA map.

Catalog record

CREATORLiu Z, Zhou Y, Liang G, Ling Y, Tan W, Tan L, Andrews R, Zhong W, Zhang X, Song E, Gong C.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6343010

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p By Zihao Liu, You Zhou, Gehao Liang, Yun Ling, Weige Tan, Luyuan Tan, Robert Andrews, Wenjing Zhong, Xuanxuan Zhang, Erwei Song, Chang Gong Published in: Cell Death & Disease DOI: 10.1038/s41419-018-1287-1 ABSTRACT Increasing evidence suggests circular RNAs (circRNAs) exert critical functions in tumor progression via sponging miRNAs (microRNAs). However, the role of circRNAs in breast cancer remains unclear. Here we systematically analyzed the circular RNAs in breast cancer based on their characteristic in sponging disease-specific miRNAs and identified hsa_circ_001783 as a top ranked circRNA in our computation and verified its high expression in both breast cancer cells and cancer tissue. A higher level of hsa_circ_001783 was significantly correlated with heavier tumor burden and poorer prognosis of patients with breast cancer. Knockdown of this circRNA remarkably inhibited the proliferation and invasion of breast cancer cells. Importantly, hsa_circ_001783 promoted progression of breast cancer cells via sponging miR-200c-3p. Taken together, hsa_circ_001783 may serve as a novel prognostic and therapeutic target for breast cancer. INTRODUCTION Breast cancer is the most frequently diagnosed cancer for women in the world1,2. Despite recent advances in early diagnosis and effective treatment, breast cancer in some patients would progress to metastatic stage after therapy without knowing the reason. Therefore, it is essential to search for novel molecules in order to understand the progression of breast cancer. Circular RNAs (circRNAs) were first detected in virus as covalently closed looped RNAs3. As next-generation sequencing technologies are developing rapidly, a number of circRNAs have been identified as functional molecules in regulating disease progression rather than splicing by-products4–6. Our previous study has demonstrated that circRNAs can promote breast cancer cells progression under hypoxia7. Others have revealed circRNAs contribute to breast cancer proliferation and invasion7–9. Further studies indicate that imperfect matches could be formed in circRNA-miRNA duplex, which enable circRNAs to serve as “miRNA sponge” and prevent miRNA-mediated degradation of mRNAs10. For example, CDR1as sponges miR-7 via its miR-7 targeting sites and regulates tumor progression11,12. CircHIPK3, circGFRA1, and hsa_circ_0001982 have been reported as functional miRNA sponges in cancers8,9,13. These studies focused on the differentially expressed circRNAs rather than elucidating their sponge ability and the role of circRNAs in breast cancer remains obscure. Thus, there is an urgent need to characterize their sponge abilities and define the associated molecular mechanism in breast cancer. In the present study, we proposed a new bioinformatics method to screen “circular sponges”. We used five algorithms to predict binding sites of human miRNAs to the conserved sequences of individual circRNAs. Simultaneously, we identified breast cancer-associated miRNAs using Ingenuity knowledge database, Pubmed, and Embase. Five essential functional features were used to score the strength associations between miRNAs and breast cancer. And the network branches across circRNA, miRNA, and breast cancer were ranked. We further assess the clinical potential and explore the molecular function of the top ranked circRNA in breast cancer. MATERIAL AND METHODS Data extraction and analysis CircRNA annotations and sequences were extracted from circBase14. MiRNA sequences were extracted from miRBase15. The conserved circRNA sequences were analyzed as described16. Five algorithms including Targetscan17, miRanda18, PITA19, RNAhybrid20, and RNA22 (ref. 21) were used to analyze the potential bindings of miRNAs to individual circRNA. The potential targets of individual miRNAs were predicted by starbase with summation of targetScan sites, picTar sites, RNA22 sites, PITA sites, and miRanda sites ≥5 (ref. 22). Two miRNA microarray datasets (GSE40056 and GSE28969) and one mRNA microarray dataset (GSE41313) were downloaded from NCBI GEO public database (www.ncbi.nlm.nih.gov/geo) and analyzed by R version 3.4.3. The log2FC > 1.5 and P < 0.05 were characterized as differentially expressed miRNAs or mRNAs. The circRNA–miRNA–mRNA was visualized by Cytoscape (version 3.6.0). The miRNA gene ontology (GO) terms “biological process” analysis was constructed by Cytoscape plug-in ClueGo23. The mRNA GO terms were analyzed by DAVID (https://david.ncifcrf.gov/). Patient samples and clinical database A total of 136 breast cancer patients aged from 18 to 70 years old enrolled Sun Yat-sen Memorial Hospital (SYSMH) between 1 June 2010 and 31 May 2015. Their paraffin-embedded tissue samples and paired non-tumorigenesis tissue samples (n = 18) were collected for RNA fluorescence in situ hybridization (FISH). Patients who received neoadjuvant chemotherapy were excluded. All the HER2 (human epidermal growth factor receptor 2)-positive patients received anti-HER2 therapy. In addition, a total of 50 fresh-frozen cancer specimens were collected from breast cancer patients who received no therapy before surgery at the Breast Tumor Center of SYSMH. The specimens were stored in RNA later (Ambion, USA) at −80 °C immediately and were used for qPCR analysis afterwards. RNA FISH Cy3-labeled oligonucleotide probe for hsa_circ_001783 and FAM-labeled oligonucleotide probe for hsa-miR-200c-3p were applied for RNA FISH. The oligonucleotide sequences are available in the Supplementary Information. Paraffin section of breast cancer samples were deparaffinized with 100% xylene and rehydrated with different graded ethanol. For RNA FISH of co-localization of hsa_circ_001783 and hsa-miR-200c-3p, cells were seeded in a glass-bottom dish. Then they were incubated with prehybridization solution at 37 °C for 30 min and the probes (Ribobio, China, 20 μM) were added to slides or dish individually and hybridized overnight. Then they were washed with buffer I (4× SSC, 0.1% Tween-20) for three times, wash with buffer II (2 × SSC) for once, and wash with buffer III (1× SSC) for once. After being washed with phosphate-buffered saline, they were incubated with DAPI to stain cell nuclear. The cells at each staining intensity were recorded on a scale of 0 (no staining), 1 (light red), 2 (red), 3 (strong red), and 4 (dark red). The staining index (SI) was calculated as follows: SI = staining intensity × proportion of positively stained cells. Positive cells in the whole fields of view were calculated. RNA-binding protein immunoprecipitation (RIP) The RIP assay was performed by Magna RIP Kit (Millipore, USA) and was conducted as previously instructed13. Briefly, 1 × 107 cells of HEK-293T were incubated with lysis buffer with protease and RNase inhibitors added. Then the cell lysis was incubated with magnetic beads which are conjugated with human ani-Argonaute2 (AGO2) antibody (Millipore, USA) or negative control IgG (Millipore, USA), respectively, at 4 °C overnight. Subsequently, samples were washed and incubated with Proteinase K. Immunoprecipitated RNA was purified and was subjected to quantitative real-time PCR analysis to determine hsa_circ_001783. CircRNA pull-down Biotin-labeled hsa_circ_001783 probe and control probe (Sangon Biotech, China) were used for circRNA pull-down and the assay was performed as mentioned previously24–26. In brief, MDA-MB-468 was cross-linked by 1% formaldehyde for 30 min, lysed in co-IP buffer, and centrifugated. The supernatant was incubated with hsa_circ_001783-specific probes-streptavidin beads (Life Technologies, USA) mixture overnight at 37 °C. On the next day, the samples were washed and incubated with lysis buffer and proteinase K. Finally, the mixture was added with TRIzol reagent for RNA extraction and followed by detection of hsa_circ_001783, hsa-miR-200c-3p, and β-actin. AGO-binding sites from PAR-CLIP data sets The AGO1 and AGO2 binding sites were acquired from published photoactivatable cross-linking immunoprecipitation (PAR-CLIP) data in GEO database (https://www.ncbi.nlm.nih.gov/geo/). Three PAR-CLIP datasets (GSE28865, GSE43573, and GSE21918) from HEK293 cells were extracted. We analyzed the AGO1 as well as AGO2 binding sites of hsa_circ_001783 genomic region. Cell lines and treatment The human non-carcinogenesis mammary epithelial cell line (MCF-10A) and human breast

Read the complete text